ARase Therapeutics
Preclinical-stage biotechnology company targeting DNA repair deficiencies in tumors for the treatment of breast, ovarian, pancreatic, lung, and prostate cancer.
Notes
ARase Therapeutics is a preclinical-stage biotechnology company focused on developing novel therapeutics targeting DNA repair deficiencies in tumors. The company's approach centers on exploiting homologous recombination deficiency (HRD) in cancer cells, particularly in breast, ovarian, pancreatic, lung, and prostate cancers.
The company is developing therapies that specifically target HRD-high tumors, which have impaired ability to repair DNA damage, making them vulnerable to specific therapeutic interventions. This approach aligns with the broader trend in precision oncology of identifying and targeting specific molecular vulnerabilities in cancer cells.
ARase Therapeutics is a portfolio company of Portal Innovations, a life sciences venture and innovation center.
Team
- Paul Chang - Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/paulchang
Additional Research Findings
- Portfolio company of Portal Innovations
- Stage: Preclinical
- Focus on HRD-high tumors
- Targeting DNA repair deficiencies in multiple solid tumor types
- Boston-based biotech startup
- Precision oncology approach
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Portal Innovations | US | biotech-focused | - | 13 |